Tier 2 — strong
Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment
Alzheimer's & dementia (New York, N. Y.)
2025
11; 1; e70023
Bibliography
- PubMed
- PMID 39817194
- PubMed Central
- PMC11733434
- Funding
- Indexed grant support includes NIA NIH HHS. The complete funding declaration is not specified in the accessible abstract.
- Competing interests
- Disclosures include a paid ChromaDex consultancy and equity holding by one author, plus other advisory and sponsored-research relationships.
Study snapshot
| Design | Randomized placebo-controlled human trial |
|---|---|
| Model | Human participants |
| Sample | 46 randomized; 41 baseline visits; 37 completed |
| Intervention | NR 1000 mg/day versus placebo |
| Duration | 8-week treatment phases |
| Endpoints | RBANS cognition; pTau217; GFAP and NfL |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- NR for Brain Health and Alzheimer’s: What the Trials FoundNR for brain health and Alzheimer’s: MCI trial results, pTau217, brain NAD+, perfusion, cognition, combinations and what remains unproven.Read analysis
- Nicotinamide Riboside Benefits: What Human Trials ShowNR benefits assessed through human trials: NAD+, walking, energy, cognition, cardiovascular health, longevity and the latest null findings.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
